Cardiff Oncology to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Cardiff Oncology, Inc. (CRDF)
Company Research
Source: GlobeNewswire
SAN DIEGO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present and participate in 1x1 investor meetings at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, being held in a virtual format February 25-26, 2026. Details of the presentation can be found below. Presenter: Mani Mohindru, PhD (Interim CEO) Date: 02/25/2026Time: 1:20 PM ET Interested parties can register for and access the live webcast for the conference by visiting the “Events” section of the Cardiff Oncology website. The webcast replay will be available after the conclusion of the presentation. About Cardiff Oncology, Inc.Cardiff Oncology is a clinical-stage biotechnology company advancing innovative cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Our l
Show less
Read more
Impact Snapshot
Event Time:
CRDF
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRDF alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRDF alerts
High impacting Cardiff Oncology, Inc. news events
Weekly update
A roundup of the hottest topics
CRDF
News
- Cardiff Oncology (CRDF) was upgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=CRDF&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "sell" tMarketBeat
- Cardiff Oncology to Participate in Three Upcoming Investor Conferences [Yahoo! Finance]Yahoo! Finance
- Cardiff Oncology to Participate in Three Upcoming Investor Conferences GlobeNewswire
- Cardiff Oncology Spotlights Onvansertib Data at Oppenheimer: 72% ORR in RAS-Mutant mCRC [Yahoo! Finance]Yahoo! Finance
- Cardiff Oncology (CRDF) had its price target lowered by Piper Sandler from $10.00 to $6.00. They now have an "overweight" rating on the stock.MarketBeat
CRDF
Earnings
- 2/24/26 - Miss
CRDF
Sec Filings
- 2/25/26 - Form 8-K
- 2/24/26 - Form 8-K
- 2/24/26 - Form 10-K
- CRDF's page on the SEC website